Shares of Eli Lilly & Co. LLY rallied 3.26% to $864.90 Monday, on what proved to be an all-around great trading session for ...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

We recently published a list of Was Jim Cramer Right About These 23 Stocks? In this article, we are going to take a look at ...

Augustine Therapeutics, a Belgian biotech developing therapies for neuromuscular, neurodegenerative and cardio-metabolic ...

Eli Lilly and Company (NYSE:LLY) offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of March 20. It is one of the best dividend stocks on our list as the company has ...

AGT-100216 will now enter a Phase I/II proof-of-concept clinical trial for CMT disease, with patient enrolment set to begin ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...

Janus Henderson is a global investment management company that provides diverse mutual funds in equities, fixed-income and multi-asset strategies. Janus Henderson was created by the 2017 merger ...

Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...